Lurasidone for the treatment of bipolar depression: an evidence-based review
Name
Franklin-2015-Lurasidone for the t.pdf
Size
531.13 KB
Format
Adobe PDF
Checksum (MD5)
baa0581aa9e5fee05bde5dc6cdef23f0
Author(s)
Deckersbach, Thilo
Widge, Alik
Franklin, Rachel
Zorowitz, Sam
Corse, Andrew
Date Issued
August 2015
Journal
Neuropsychiatric Disease and Treatment
Publisher
Dove Medical Press
Citation
Deckersbach, Thilo, Alik Widge, Rachel Franklin, Sam Zorowitz, and Andrew Corse. “Lurasidone for the Treatment of Bipolar Depression: An Evidence-Based Review.” Neuropsychiatric Disease and Treatment (August 2015): 2143.
Version
Final published version
Abstract
Bipolar disorder (BD) is a debilitating and difficult-to-treat psychiatric disease that presents a serious burden to patients’ lives as well as health care systems around the world. The essential diagnostic criterion for BD is episodes of mania or hypomania; however, the patients report that the majority of their time is spent in a depressive phase. Current treatment options for this component of BD have yet to achieve satisfactory remission rates. Lurasidone is a drug in the benzisothiazole class approved by the US Food and Drug Administration in June 2013 for the acute treatment of bipolar depression. Its pharmacological profile features high-affinity antagonism at D[subscript 2], 5-HT[subscript 2A], and 5-HT[subscript 7] receptors; moderate-affinity antagonism at α[subscript 2C]-adrenergic receptors; low- to very low-affinity antagonism at α[subscript 1A]-adrenergic, α[subscript 2A]-adrenergic, H[subscript 1], M[subscript 1], and 5-HT[subscript 2C] receptors; and high-affinity partial agonism at 5-HT1A. Preliminary findings from two recent double-blinded clinical trials suggest that lurasidone is efficacious in treating bipolar I depression, with clinical effects manifesting as early as the first 2–3 weeks of treatment (as measured by the Montgomery–Åsberg Depression Rating Scale and Clinical Global Impressions Scale for use in bipolar illness). Its therapeutic benefit appears to be comparable to the current US Food and Drug Administration-indicated treatments: quetiapine and olanzapine–fluoxetine, according to a measure of effect size known as number needed to treat. These studies reported relatively limited extrapyramidal and metabolic side effects as a result of treatment with lurasidone, with the most common side effect being nausea. Safety data drawn from these studies, as well as a more extensive body of schizophrenia research, indicate that in comparison with other atypical antipsychotics, treatment with lurasidone is less likely to result in metabolic side effects such as weight gain or disturbances of serum glucose or lipid levels. Lurasidone holds clinical potential as a novel, efficacious pharmacological treatment for bipolar depression. However, current data on its use for the treatment of BD are limited, and more extensive research, both longer in duration as well as independently conducted, is needed.
MIT Department
Picower Institute for Learning and Memory
Terms of Use
Creative Commons Attribution
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.2147/ndt.s50961
